<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Piccirillo SG</submitter><funding>Cancer Research UK</funding><funding>Medical Research Council</funding><funding>National Institute for Health Research (NIHR)</funding><funding>The Brain Tumour Charity</funding><funding>Wellcome Trust</funding><pagination>194-202</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4286248</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>75(1)</volume><pubmed_abstract>Glioblastoma, the most common and aggressive adult brain tumor, is characterized by extreme phenotypic diversity and treatment failure. Through fluorescence-guided resection, we identified fluorescent tissue in the sub-ependymal zone (SEZ) of patients with glioblastoma. Histologic analysis and genomic characterization revealed that the SEZ harbors malignant cells with tumor-initiating capacity, analogous to cells isolated from the fluorescent tumor mass (T). We observed resistance to supramaximal chemotherapy doses along with differential patterns of drug response between T and SEZ in the same tumor. Our results reveal novel insights into glioblastoma growth dynamics, with implications for understanding and limiting treatment resistance.</pubmed_abstract><journal>Cancer research</journal><pubmed_title>Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone.</pubmed_title><pmcid>PMC4286248</pmcid><funding_grant_id>C1023/A14545</funding_grant_id><funding_grant_id>19556</funding_grant_id><funding_grant_id>G1001522</funding_grant_id><funding_grant_id>NIHR/CS/009/011</funding_grant_id><funding_grant_id>A14545</funding_grant_id><funding_grant_id>090340</funding_grant_id><funding_grant_id>MC_UU_12022/1</funding_grant_id><funding_grant_id>A10825</funding_grant_id><funding_grant_id>C14303/A10825</funding_grant_id><funding_grant_id>MC_UU_12022/8</funding_grant_id><funding_grant_id>10/136</funding_grant_id><funding_grant_id>16700</funding_grant_id><funding_grant_id>14545</funding_grant_id><pubmed_authors>Venkitaraman AR</pubmed_authors><pubmed_authors>Spiteri I</pubmed_authors><pubmed_authors>Curtis C</pubmed_authors><pubmed_authors>Collins VP</pubmed_authors><pubmed_authors>Piccirillo SG</pubmed_authors><pubmed_authors>Watts C</pubmed_authors><pubmed_authors>Francis NJ</pubmed_authors><pubmed_authors>Ber S</pubmed_authors><pubmed_authors>Heywood R</pubmed_authors><pubmed_authors>Howarth KD</pubmed_authors><pubmed_authors>Touloumis A</pubmed_authors><pubmed_authors>Sottoriva A</pubmed_authors><pubmed_authors>Tavare S</pubmed_authors><pubmed_authors>Marioni JC</pubmed_authors><pubmed_authors>Price SJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone.</name><description>Glioblastoma, the most common and aggressive adult brain tumor, is characterized by extreme phenotypic diversity and treatment failure. Through fluorescence-guided resection, we identified fluorescent tissue in the sub-ependymal zone (SEZ) of patients with glioblastoma. Histologic analysis and genomic characterization revealed that the SEZ harbors malignant cells with tumor-initiating capacity, analogous to cells isolated from the fluorescent tumor mass (T). We observed resistance to supramaximal chemotherapy doses along with differential patterns of drug response between T and SEZ in the same tumor. Our results reveal novel insights into glioblastoma growth dynamics, with implications for understanding and limiting treatment resistance.</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Jan</publication><modification>2026-04-29T12:28:11.869Z</modification><creation>2019-03-27T01:42:53Z</creation></dates><accession>S-EPMC4286248</accession><cross_references><pubmed>25406193</pubmed><doi>10.1158/0008-5472.can-13-3131</doi><doi>10.1158/0008-5472.CAN-13-3131</doi></cross_references></HashMap>